• Please log in or register to access this feature.
You have free access to this content

High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy

  1. Z. Zelinkova1,
  2. C. de Haar1,
  3. L. de Ridder2,
  4. M. J. Pierik3,
  5. E. J. Kuipers1,4,
  6. M. P. Peppelenbosch1,
  7. C. J. van der Woude1

Article first published online: 1 MAR 2011

DOI: 10.1111/j.1365-2036.2011.04617.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 33, Issue 9, pages 1053–1058, May 2011

Additional Information

How to Cite

Zelinkova, Z., de Haar, C., de Ridder, L., Pierik, M. J., Kuipers, E. J., Peppelenbosch, M. P. and van der Woude, C. J. (2011), High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Alimentary Pharmacology & Therapeutics, 33: 1053–1058. doi: 10.1111/j.1365-2036.2011.04617.x

Author Information

  1. 1

    Department of Gastroenterology & Hepatology, Erasmus MC, Rotterdam, The Netherlands.

  2. 2

    Department of Pediatric Gastroenterology, Erasmus MC, Rotterdam, The Netherlands.

  3. 3

    Department of Gastroenterology & Hepatology, University Medical Center, Maastricht, The Netherlands.

  4. 4

    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.

*Dr Z. Zelinkova, Department of Gastroenterology & Hepatology, Erasmus MC, PO Box 2040, NL-3000 CA Rotterdam, The Netherlands. E-mail: z.zelinkova@erasmusmc.nl

Publication History

  1. Issue published online: 1 APR 2011
  2. Article first published online: 1 MAR 2011
  3. Publication data Submitted 10 January 2011 First decision 27 January 2011 Resubmitted 11 February 2011 Accepted 11 February 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (126K)

References

  • 1
    Zelinkova Z, Mensink PB, Dees J, et al. Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases. Scand J Gastroenterol 2010; 45: 46–50.
  • 2
    Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385–92.
    Direct Link:
  • 3
    Lichtenstein GR, Cohen RD, Feagan BG, et al. Safety of infliximab in Crohn`s disease: data from 5000-patients TREAT registry. Gastroenterology 2004; 126: A54.
  • 4
    Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255–8.
  • 5
    Mahadevan U, Terdiman JP, Church J, et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2007; 132: A144.
  • 6
    Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228–33.
  • 7
    Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010; 16: 881–95.
    Direct Link:
  • 8
    Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn`s disease: special situations. J Crohn`s Colitis 2010; 4: 63–101.
  • 9
    Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immnosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006; 28: 169–74.
  • 10
    Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011 [Epub ahead of print].
    Direct Link:
  • 11
    Finley WH, Gustavson KH, Hall TM, et al. Birth defect surveillance: Jefferson County, Alabama, and Uppsala County, Sweden. South Med J 1994; 87: 440–5.
  • 12
    Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999; 92: 551–63.
  • 13
    Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol 2009; 43: 613–6.
  • 14
    Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003; 170: 3528–33.
  • 15
    Baker K, Qiao SW, Kuo T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol 2009; 31: 223–36.
  • 16
    Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21: 3365–9.
  • 17
    Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 2009; 86: 328–44.
    Direct Link:
  • 18
    Mahadevan U, Kane SV, Church JA, et al. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008; 134: A69.
  • 19
    Cheent K, Nolan J, Shariq S, et al. Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn`s disease. J Crohn`s Colitis 2010; 4: 603–5.
  • 20
    Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 2007; 13: 1024–30.
    Direct Link:
  • 21
    Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30: 523–9.
View Full Article (HTML) Get PDF (126K)